Literature DB >> 26250491

Impact of HIV infection and smoking on lung immunity and related disorders.

Theresa M Rossouw1, Ronald Anderson2, Charles Feldman3.   

Abstract

HIV-infected persons not only have higher rates of smoking than the general population, but are also unusually vulnerable to the associated adverse health effects, both infective and noninfective in origin. Indeed, in the setting of well-organised care and availability of highly active antiretroviral therapy, HIV-infected smokers lose more life-years to smoking than to HIV infection per se, presenting a major challenge to healthcare providers. Not surprisingly, the respiratory system is particularly susceptible to the damaging interactive chronic inflammatory and immunosuppressive effects of HIV and smoking, intensifying the risk of the development of opportunistic infections, as well as lung cancer and obstructive lung disorders. The impact of smoking on the immunopathogenesis and frequencies of these respiratory conditions in the setting of HIV infection, as well as on the efficacy of antiretroviral therapy, represent the primary focus of this review.
Copyright ©ERS 2015.

Entities:  

Mesh:

Year:  2015        PMID: 26250491     DOI: 10.1183/13993003.00353-2015

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  17 in total

1.  Emphysema and soluble CD14 are associated with pulmonary nodules in HIV-infected patients: implications for lung cancer screening.

Authors:  Matthew Triplette; Keith M Sigel; Alison Morris; Shahida Shahrir; Juan P Wisnivesky; Chung Y Kong; Phillip T Diaz; Alycia Petraglia; Kristina Crothers
Journal:  AIDS       Date:  2017-07-31       Impact factor: 4.177

2.  The Differential Impact of Emphysema on Respiratory Symptoms and 6-Minute Walk Distance in HIV Infection.

Authors:  Matthew Triplette; Engi Attia; Kathleen Akgün; Monica Campo; Maria Rodriguez-Barradas; Sudhakar Pipavath; Shahida Shahrir; Cherry Wongtrakool; Matthew Goetz; Joon Kim; Guy W Soo Hoo; Sheldon T Brown; Kristina Crothers
Journal:  J Acquir Immune Defic Syndr       Date:  2017-01-01       Impact factor: 3.731

Review 3.  Harm reduction for smokers living with HIV.

Authors:  Jonathan Shuter; Krishna P Reddy; Emily P Hyle; Cassandra A Stanton; Nancy A Rigotti
Journal:  Lancet HIV       Date:  2021-08-27       Impact factor: 16.070

Review 4.  The respiratory microbiome of HIV-infected individuals.

Authors:  M B Lawani; A Morris
Journal:  Expert Rev Anti Infect Ther       Date:  2016-08       Impact factor: 5.091

Review 5.  Non-infectious Pulmonary Diseases and HIV.

Authors:  M Triplette; K Crothers; E F Attia
Journal:  Curr HIV/AIDS Rep       Date:  2016-06       Impact factor: 5.071

6.  Systemic Immune Activation Profiles of HIV-1 Subtype C-Infected Children and Their Mothers.

Authors:  Tinyiko G Makhubele; Helen C Steel; Ronald Anderson; Gisela van Dyk; Annette J Theron; Theresa M Rossouw
Journal:  Mediators Inflamm       Date:  2016-02-25       Impact factor: 4.711

Review 7.  Global impact of bronchiectasis and cystic fibrosis.

Authors:  Margarida Redondo; Holly Keyt; Raja Dhar; James D Chalmers
Journal:  Breathe (Sheff)       Date:  2016-09

8.  Clinical and computed tomography findings in Chinese lung cancer patients with HIV infection: A multi-center study.

Authors:  Zenghui Cheng; Fei Shan; Jinxin Liu; Yuxin Shi; Zhiyong Zhang; Guowei Wu
Journal:  Thorac Cancer       Date:  2017-03-15       Impact factor: 3.500

Review 9.  The Role of Transforming Growth Factor Beta-1 in the Progression of HIV/AIDS and Development of Non-AIDS-Defining Fibrotic Disorders.

Authors:  Annette J Theron; Ronald Anderson; Theresa M Rossouw; Helen C Steel
Journal:  Front Immunol       Date:  2017-11-02       Impact factor: 7.561

10.  Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States.

Authors:  Krishna P Reddy; Chung Yin Kong; Emily P Hyle; Travis P Baggett; Mingshu Huang; Robert A Parker; A David Paltiel; Elena Losina; Milton C Weinstein; Kenneth A Freedberg; Rochelle P Walensky
Journal:  JAMA Intern Med       Date:  2017-11-01       Impact factor: 44.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.